Doctors Say GLP-1 Drugs Cut Heart Risks but Carry 10- to 20-Year Unknowns

4 articles · Updated · East Idaho News · May 18

GLP-1 drugs have a strong safety record so far, doctors said, with trials over several years showing significant weight loss, better blood sugar control and lower heart attack and stroke risk.
The best-documented side effects are gastrointestinal—nausea, vomiting, diarrhea and constipation—while rarer serious problems included pancreatitis, gallbladder issues and worsening diabetic retinopathy in some patients.
Long-term safety remains unclear because newer drugs such as Ozempic, approved in 2017, and Wegovy, approved in 2021, lack 10- to 20-year human data on possible pancreas, thyroid or other organ effects.
Real-world use is also surfacing complications less obvious in trials, including severe gastroparesis and aspiration during anesthesia, with the FDA and manufacturers still monitoring reports.
Pregnant or breastfeeding patients, and people with pancreatitis history, medullary thyroid cancer, MEN2 or severe gastroparesis, were flagged as poor candidates despite the drugs being generally safe when medically supervised.

Could a genetic test soon predict if you will succeed or suffer on weight-loss drugs like Ozempic?

Beyond weight loss, are these drugs an unexpected new weapon against addiction and even cancer?

As millions begin lifelong use, what are the hidden health consequences of these 'miracle' drugs?